Animal models of toxicology testing: The role of pigs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 2, 2013, Pages 127-139

  Helke, Kristi L ^a   Swindle, Marvin Michael ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cytochrome P450; Drug metabolism; Kidney; Liver; Pig; Skin; Toxicology

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2A; CYTOCHROME P450 3A; CYTOCHROME P450 4A; ENZYME; XENOBIOTIC AGENT;

ANIMAL MODEL; BIOTRANSFORMATION; BREEDING; DRUG METABOLISM; GASTROINTESTINAL TRACT; HUMAN; LIVER; NONHUMAN; REVIEW; RODENT; SKIN; SPECIES; SWINE; TOXICITY TESTING;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG TOXICITY; HUMANS; MODELS, ANIMAL; SPECIES SPECIFICITY; SUS SCROFA; SWINE; SWINE, MINIATURE; TOXICITY TESTS;

ANIMALIA; CANIS FAMILIARIS; PRIMATES; RODENTIA; SUIDAE;

EID: 84872440155     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.739607     Document Type: Review

References (124)

1. Forster R, Ancian P, Fredholm M, et al. The minipig as a platform for new technologies in toxicology. J Pharmacol Toxicol Methods 2010;62(3):227-35
2. Forster R, Bode G, Ellegaard L, van der Laan JW. The RETHINK project-minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment. J Pharmacol Toxicol Methods 2010;62(3):158-9
3. van der Laan JW, Brightwell J, McAnulty P, et al. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. J Pharmacol Toxicol Methods 2010;62(3):184-95
4. Webster J, Bollen P, Grimm H, Jennings M. Ethical implications of using the minipig in regulatory toxicology studies. J Pharmacol Toxicol Methods 2010;62(3):160-6
5. Swindle MM, Makin A, Herron AJ, et al. Swine as models in biomedical research and toxicology testing. Vet Pathol 2012;49(2):344-56
6. Bode G, Clausing P, Gervais F, et al. The utility of the minipig as an animal model in regulatory toxicology. J Pharmacol Toxicol Methods 2010;62(3):196-220
7. Olejniczak K, Gunzel P, Bass R. Preclinical testing strategies. Drug Inf J 2001;35(2):321-36
8. ICH Harmonised Tripartite Guideline. Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6 (R1), 2011
9. Valentin JP, Bass AS, Atrakchi A, et al. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A. J Pharmacol Toxicol Methods 2005;52(1):22-9 (Pubitemid 41008627)
10. ICH Guideline for industry: toxicokinetics: the assessment of systemic exposure in toxicity studies S3A, 1995
11. Puccinelli E, Gervasi PG, Longo V. Xenobiotic metabolizing cytochrome P450 in pig, a promising animal model. Curr Drug Metab 2011;12(6):507-25
12. Swindle MM. Swine in the laboratory: surgery, anesthesia, imaging, and experimental techniques. 2nd edition. CRC Press; Boca Raton, FL; 2007
13. Archibald A, Bolund L, Churcher C, et al. Pig genome sequence - analysis and publication strategy. BMC Genomics 2010;11(1):438
14. Merrifield CA, Lewis M, Claus SP, et al. A metabolic system-wide characterisation of the pig: a model for human physiology. Mol Biosyst 2011;7(9):2577-88
15. Anzenbacher P, Soucek P, Anzenbacherova E, et al. Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples. Drug Metab Dispos 1998;26(1):56-9 (Pubitemid 28071325)
16. Hannon JP, Bossone CA, Wade CE. Normal physiological values for conscious pigs used in biomedical research. Lab Anim Sci 1990;40(3):293-8 (Pubitemid 20198131)
17. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995;16(5):351-80
18. Thorn HA. First-pass intestinal metabolism of drugs; experiences from in vitro, in vivo and simulation studies. Uppsala Universitet; Uppsala, Sweden: 2012
19. Swindle MM, Smith AC. Comparative anatomy and physiology of the pig. Scand J Lab Anim Sci 1998;25(Suppl 1):11-21 (Pubitemid 128549607)
20. Bogaards JJ, Bertrand M, Jackson P, et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000;30(12):1131-52 (Pubitemid 32368013)
21. Nebbia C, Dacasto M, Rossetto Giaccherino A, et al. Comparative expression of liver cytochrome P450-dependent monooxygenases in the horse and in other agricultural and laboratory species. Vet J 2003;165(1):53-64 (Pubitemid 38001823)
22. Skaanild MT, Friis C. Cytochrome P450 sex differences in minipigs and conventional pigs. Pharmacol Toxicol 1999;85(4):174-80 (Pubitemid 29484983)
23. Merchant HA, McConnell EL, Liu F, et al. Assessment of gastrointestinal pH, fluid and lymphoid tissue in the guinea pig, rabbit and pig, and implications for their use in drug development. Eur J Pharm Sci 2011;42(1-2):3-10
24. Kvetina J, Svoboda Z, Nobilis M, et al. Experimental Goettingen minipig and beagle dog as two species used in bioequivalence studies for clinical pharmacology (5-aminosalicylic acid and atenolol as model drugs). Gen Physiol Biophys 1999;18(Spec No):80-5
25. Smith DH, Chen XH, Nonaka M, et al. Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol 1999;58(9):982-92 (Pubitemid 29441926)
26. Thim T, Hagensen MK, Drouet L, et al. Familial hypercholesterolaemic downsized pig with human-like coronary atherosclerosis: a model for preclinical studies. EuroIntervention 2010;6(2):261-8
27. Mikkelsen M, Moller A, Jensen LH, et al. MPTP-induced Parkinsonism in minipigs: a behavioral, biochemical, and histological study. Neurotoxicol Teratol 1999;21(2):169-75 (Pubitemid 29127143)
28. Nunoya T. Kazumoto, S, Toshiki, S, et al. Use of miniature pig for biomedical research, with reference to toxicologic studies. J Toxicol Pathol 2007;20:125-32
29. Lehmann H. The minipig in general toxicology. Scand J Lab Anim Sci 1998;25(Suppl 1):59-62 (Pubitemid 128549613)
30. Wiseman E. Review of preclinical studies with piroxicam: Pharmacology, pharmacokinetics and toxicology. Royal society of medicine. International Congress and Symposium Series Academic Press, Inc. Ltd., and Royal Society of Medicine, London; 1978. p. 11-23
31. Dogterom P, Zbinden G, Reznik GK. Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview. Crit Rev Toxicol 1992;22(3-4):203-41
32. Rona G, Zsoter T, Chappel C, Gaudry R. Myocardial lesions, circulatory and electrocardiographic changes produced by isoproterenol in the dog. Rev Can Biol 1959;18(1):83-94
33. Schneider P, Guttner J, Eckenfels A, et al. Comparative cardiac toxicity of the i.v. administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs. Exp Toxicol Pathol 1997;49(3-4):217-24 (Pubitemid 27380471)
34. Fink-Gremmels J. Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. Eur J Pharmacol 2008;585(2-3):502-9
35. Anzenbacherova E, Anzenbacher P, Svoboda Z, et al. Minipig as a model for drug metabolism in man: comparison of in vitro and in vivo metabolism of propafenone. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147(2):155-9
36. Zuber R, Anzenbacherova E, Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 2002;6(2):189-98 (Pubitemid 44137197)
37. Soucek P, Zuber R, Anzenbacherova E, et al. Minipig cytochrome P450 3A 2A and 2C enzymes have similar properties to human analogs. BMC Pharmacol 2001;1:11
38. The human cytochrome P450 (CYP) allele nomenclature database. Available from: http://cypalleles.ki.se/ [Last accessed 5 July 2012]
39. Harbach PR, Wiser SK, Smith AL, et al. Strain differences in in vitro rat hepatocyte unscheduled DNA synthesis (UDS): effect of UV is independent of strain while increased sensitivity is apparent using Fischer-344 instead of Sprague-Dawley rats. Mutat Res 1991;252(2):149-55
40. Toutain PL, Ferran A, Bousquet-Melou A. Species differences in pharmacokinetics and pharmacodynamics. Handb Exp Pharmacol 2010(199):19-48
41. Paulson SK, Engel L, Reitz B, et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 1999;27(10):1133-42 (Pubitemid 29463599)
42. Sakuma T, Shimojima T, Miwa K, Kamataki T. Cloning CYP2D21 and CYP3A22 cDNAs from liver of miniature pigs. Drug Metab Dispos 2004;32(4):376-8 (Pubitemid 38420269)
43. Vaclavikova R, Soucek P, Svobodova L, et al. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos 2004;32(6):666-74 (Pubitemid 38668160)
44. Lawhorn B. Diseases and conditions of miniature pet pigs. In: Reeves D, editor. Care and management of miniature pet pigs. 1st edition. Veterinary Practice Publishing Co; Santa Barbara, CA; 1993. p. 77-100
45. Larsen MO, Rolin B. Use of the Gottingen minipig as a model of diabetes, with special focus on type 1 diabetes research. ILAR J 2004;45(3):303-13
46. Misfeldt ML, Grimm DR. Sinclair miniature swine: an animal model of human melanoma. Vet Immunol Immunopathol 1994;43(1-3):167-75 (Pubitemid 24327541)
47. Oshima S, Sato H, Nagase S, et al. A new strain of small-sized pig originating from a Chinese breed. Jikken Dobutsu Exp Anim 1973;22(Suppl 0):253-9
48. Nakanishi Y. Body measurements and some characteristics of inbred CLAWN miniature pigs. Jpn J Swine Sci 1981;28:211-18
49. Liu Y, Zeng BH, Shang HT, et al. Bama miniature pigs (Sus scrofa domestica) as a model for drug evaluation for humans: comparison of in vitro metabolism and in vivo pharmacokinetics of lovastatin. Comp Med 2008;58(6):580-7
50. Wu J, Ma Y, Lv M, et al. Large-scale survey of porcine endogenous retrovirus in Chinese miniature pigs. Comp Immunol Microbiol Infect Dis 2008;31(4):367-71 (Pubitemid 351716019)
51. Kohn F. History and development of miniature, micro- and minipigs. In: McAnulty P, Dayan AD, Ganderup N-C, Hastings K, editors. The minipig in biomedical research. CRC Press; Boca Raton, FL; 2012. p. 1-15
52. Simianer H, Kohn F. Genetic management of the Gottingen minipig population. J Pharmacol Toxicol Methods 2010;62(3):221-6
53. Panepinto LM, Phillips RW, Wheeler LR, Will DH. The Yucatan miniature pig as a laboratory animal. Lab Anim Sci 1978;28(3):308-13 (Pubitemid 8391651)
54. Hanford TM Miniature Swine. Sinclair BioResoures. 2009.Available from: http://www. sinclairbioresources.com/Products/Hanford.aspx [Last accessed 18 Jun 2012]
55. Millikan LE, Boylon JL, Hook RR, Manning PJ. Melanoma in sinclair swine: a new animal model. J Invest Dermatol 1974;62(1):20-30
56. The Gottingen minipig. Ellegaard Gottingen Minipigs. 2010.Available from: http://minipigs.dk/thegottingenminipig/ [Last accessed 18 Jun 2012]
57. Watanabe T, Hayashi Y, Kimura J, et al. Pig mitochondrial DNA: polymorphism, restriction map orientation, and sequence data. Biochem Genet 1986;24(5-6):385-96 (Pubitemid 16087054)
58. Yabuki A, Kamimura R, Setoyama K, et al. Skin morphology of the CLAWN miniature pig. Exp Anim 2007;56(5):369-73 (Pubitemid 350302993)
59. Wang X, Ou J, Huang L, et al. Genetic characteristics of inbred Wuzhishan miniature pigs, a native Chinese breed. J Reprod Dev 2006;52(5):639-43 (Pubitemid 44706387)
60. Zeng R, Zeng YZ. Molecular cloning and characterization of SLA-DR genes in the 133-family of the Banna mini-pig inbred line. Anim Genet 2005;36(3):267-9 (Pubitemid 40802093)
61. Li J, Liu Y, Zhang JW, et al. Characterization of hepatic drug-metabolizing activities of Bama miniature pigs (Sus scrofa domestica): comparison with human enzyme analogs. Comp Med 2006;56(4):286-90 (Pubitemid 44313700)
62. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Molinoff PB, Ruddon RW, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th edition. McGraw-Hill, New York; 1996. p. 3-27
63. Desille M, Corcos L, L'Helgoualc'h A, et al. Detoxifying activity in pig livers and hepatocytes intended for xenotherapy. Transplantation 1999;68(10):1437-43
64. Lock EA, Reed CJ. Xenobiotic metabolizing enzymes of the kidney. Toxicol Pathol 1998;26(1):18-25 (Pubitemid 28100684)
65. Monshouwer M, Van't Klooster GA, Nijmeijer SM, et al. Characterization of cytochrome P450 isoenzymes in primary cultures of pig hepatocytes. Toxicol In Vitro 1998;12(6):715-23 (Pubitemid 28555843)
66. Lu C, Li AP. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 2001;134(3):271-81 (Pubitemid 32406149)
67. Skaanild MT. Porcine cytochrome P450 and metabolism. Curr Pharm Des 2006;12(11):1421-7 (Pubitemid 44096578)
68. Myers MJ, Farrell DE, Howard KD, Kawalek JC. Identification of multiple constitutive and inducible hepatic cytochrome P450 enzymes in market weight swine. Drug Metab Dispos 2001;29(6):908-15 (Pubitemid 32488650)
69. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34(1-2):83-448 (Pubitemid 34311090)
70. Kojima M, Morozumi T. Cloning of six full-length cDNAs encoding pig cytochrome P450 enzymes and gene expression of these enzymes in the liver and kidney. J Health Sci 2004;50(5):518-29 (Pubitemid 41295297)
71. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-23 (Pubitemid 24229655)
72. Skaanild MT, Friis C. Characterization of the P450 system in Gottingen minipigs. Pharmacol Toxicol 1997;80(Suppl 2):28-33
73. Chirulli V, Marvasi L, Zaghini A, et al. Inducibility of AhR-regulated CYP genes by beta-naphthoflavone in the liver, lung, kidney and heart of the pig. Toxicology 2007;240(1-2):25-37 (Pubitemid 47449722)
74. Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 1997;25(10):1130-6 (Pubitemid 27446582)
75. Lewis DF, Lake BG. Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions. Xenobiotica 2002;32(7):547-61 (Pubitemid 34785754)
76. Skaanild MT, Friis C. Porcine CYP2A polymorphisms and activity. Basic Clin Pharmacol Toxicol 2005;97(2):115-21 (Pubitemid 41021112)
77. Puccinelli E, Gervasi PG, La Marca M, et al. Expression and inducibility by phenobarbital of CYP2C33, CYP2C42 CYP2C49, CYP2B22, and CYP3As in porcine liver, kidney, small intestine, and nasal tissues. Xenobiotica 2010;40(8):525-35
78. Behnia K, Bhatia S, Jastromb N, et al. Xenobiotic metabolism by cultured primary porcine hepatocytes. Tissue Eng 2000;6(5):467-79
79. Yao M, Dai M, Liu Z, et al. Comparison of the substrate kinetics of pig CYP3A29 with pig liver microsomes and human CYP3A4. Biosci Rep 2011;31(3):211-20
80. Lundell K, Hansson R, Wikvall K. Cloning and expression of a pig liver taurochenodeoxycholic acid 6alpha-hydroxylase (CYP4A21): a novel member of the CYP4A subfamily. J Biol Chem 2001;276(13):9606-12
81. Lundell K. Cloning and expression of two novel pig liver and kidney fatty acid hydroxylases [cytochrome P450 (CYP) 4A24 and CYP4A25]. Biochem J 2002;363(Pt 2):297-303 (Pubitemid 34415766)
82. Anzenbacher P, Anzerbacherova E, Zuber R, et al. Pig and minipig cytochromes P450. Drug Metab Dispos 2002;30(1):100-2
83. Freudenthal RI, Leber P, Emmerling D, et al. Characterization of the hepatic microsomal mixed-function oxidase enzyme system in miniature pigs. Drug Metab Dispos 1976;4(1):25-7
84. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, et al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 2006;27(5):447-86 (Pubitemid 43363339)
85. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106(1):97-132 (Pubitemid 40386722)
86. Miners JO, Smith PA, Sorich MJ, et al. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 2004;44:1-25 (Pubitemid 38268090)
87. Baggot JD. Pharmacokinetic-pharmacodynamic relationship. Ann Rech Vet 1990;21(Suppl 1):29S-40S
88. Martinez M, Amidon G, Clarke L, et al. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. Adv Drug Deliv Rev 2002;54(6):825-50 (Pubitemid 35284013)
89. Lohr JW, Willsky GR, Acara MA. Renal drug metabolism. Pharmacol Rev 1998;50(1):107-41 (Pubitemid 28158844)
90. Murayama N, Kaneko N, Horiuchi K, et al. Cytochrome P450-dependent drug oxidation activity of liver microsomes from Microminipigs, a possible new animal model for humans in non-clinical studies. Drug Metab Pharmacokinet 2009;24(4):404-8
91. Donato MT, Castell JV, Gomez-Lechon MJ. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models. J Hepatol 1999;31(3):542-9 (Pubitemid 29408740)
92. Jurima-Romet M, Casley WL, Leblanc CA, Nowakowska M. Evidence for the catalysis of dextromethorphan O-demethylation by a CYP2D6-like enzyme in pig liver. Toxicol In Vitro 2000;14(3):253-63 (Pubitemid 30235123)
93. Thorn HA, Lundahl A, Schrickx JA, et al. Drug metabolism of CYP3A4 CYP2C9 and CYP2D6 substrates in pigs and humans. Eur J Pharm Sci 2011;43(3):89-98
94. Fraslin JM, Kneip B, Vaulont S, et al. Dependence of hepatocyte-specific gene expression on cell-cell interactions in primary culture. EMBO J 1985;4(10):2487-91
95. Lennernas H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007;37(10-11):1015-51 (Pubitemid 350035536)
96. Sugano K, Kansy M, Artursson P, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 2010;9(8):597-614
97. Lang J, Blikslager A, Regina D, et al. Synergistic effect of hydrochloric acid and bile acids on the pars esophageal mucosa of the porcine stomach. Am J Vet Res 1998;59(9):1170-6 (Pubitemid 128472443)
98. Akimoto M, Nagahata N, Furuya A, et al. Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Eur J Pharm Biopharm 2000;49(2):99-102 (Pubitemid 30126056)
99. Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 1999;46(3):183-96 (Pubitemid 29299969)
100. Aoyagi N, Ogata H, Kaniwa N, et al. Gastric emptying of tablets and granules in humans, dogs, pigs, and stomach-emptying-controlled rabbits. J Pharm Sci 1992;81(12):1170-4 (Pubitemid 23018121)
101. Jamei M, Turner D, Yang J, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009;11(2):225-37
102. van Meer G, Simons K. The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells. EMBO J 1986;5(7):1455-64
103. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215-36
104. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62(3):248-60 (Pubitemid 27417790)
105. Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002;72(5):584-94 (Pubitemid 36237730)
106. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997. 94(5):2031-5 (Pubitemid 27113956)
107. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101(2):289-94 (Pubitemid 28067324)
108. Zolnerciks JK, Booth-Genthe CL, Gupta A, et al. Substrate- and species-dependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions. J Pharm Sci 2011;100(8):3055-61
109. Persson EM, Nordgren A, Forsell P, et al. Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model. Eur J Pharm Sci 2008;34(1):22-9
110. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003;43:149-73 (Pubitemid 37372638)
111. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283(3):1552-62 (Pubitemid 28016533)
112. Yang J, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther 2004;76(4):391 (Pubitemid 39313131)
113. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 2001;33(3-4):273-97 (Pubitemid 33136266)
114. Anders MW. Metabolism of drugs by the kidney. Kidney Int 1980;18(5):636-47 (Pubitemid 11204064)
115. Sun X, Zhang L, Cheng J, et al. Study of renal function matching between Banna Minipig Inbred line and human. Transplant Proc 2004;36(8):2488-9 (Pubitemid 39550886)
116. Oesch F, Fabian E, Oesch-Bartlomowicz B, et al. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 2007;39(4):659-98 (Pubitemid 350208728)
117. Rangarajan M, Zatz JL. Effect of formulation on the delivery and metabolism of alpha-tocopheryl acetate. J Cosmet Sci 2001;52(4):225-36
118. Baron JM, Holler D, Schiffer R, et al. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol 2001;116(4):541-8 (Pubitemid 32299843)
119. Gupta VK, Zatz JL, Rerek M. Percutaneous absorption of sunscreens through micro-yucatan pig skin in vitro. Pharm Res 1999;16(10):1602-7 (Pubitemid 29510559)
120. Schmook FP, Meingassner JG, Billich A. Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm 2001;215(1-2):51-6 (Pubitemid 32206603)
121. Shang H, Yang J, Liu Y, Wei H. Tissue distribution of CYP3A29 mRNA expression in Bama miniature pig by quantitative reverse transcriptase- polymerase chain reaction (RT-PCR). Xenobiotica 2009;39(6):423-9
122. Dressler WE, Appelqvist T. Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine. Food Chem Toxicol 2006;44(3):371-9 (Pubitemid 41779437)
123. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32(1):56-67
124. Rozencweig M, Von Hoff DD, Staquet MJ, et al. Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials 1981;4(1):21-8 (Pubitemid 11128819)